Method for treating cardiovascular disease through adjunctive photodynamic therapy

Photodynamic Therapy (PDT) is used as an adjunctive or stand alone procedure for the treatment of cardiovascular disease. When used as an adjunctive therapy to Percutaneous Transluminal Coronary Angioplasty, laser angioplasty, atherectomy, stenting, or any other interventional or surgical procedure,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
1. Verfasser: HUGH L. NARCISO JR
Format: Patent
Sprache:eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator HUGH L. NARCISO JR
description Photodynamic Therapy (PDT) is used as an adjunctive or stand alone procedure for the treatment of cardiovascular disease. When used as an adjunctive therapy to Percutaneous Transluminal Coronary Angioplasty, laser angioplasty, atherectomy, stenting, or any other interventional or surgical procedure, it has been found that the treatment timing is critical to the success of the combined therapies. A photosensitizer is administered prior to the surgical or interventional procedure and then readministered after the procedure to maintain the photosensitizer concentration level in the atheromatous plaque and smooth muscle cells in the vicinity of the lesion for a period of about 5-18 days, the period in which cell proliferation can occur. The photosensitizer inhibits smooth muscle cell proliferation and, thus, minimizes or eliminates the possibility of re-stenosis. The photosensitizer is then illuminated at the end of this period, thereby lysing the atheromatous plaque and smooth muscles. The photosensitizer inhibits atheromatic smooth muscle cell proliferation.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_AU670820BB2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>AU670820BB2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_AU670820BB23</originalsourceid><addsrcrecordid>eNqNyrEKwjAQgOEsDqK-w72AUCqoqxXFxUV0LkdybVJqLlwuhb69Dj6A0z98_9I87qSeHXQsoEKoIfZgUVzgCbMtIwq4kAkzgXrh0ntAN5RoNUwEybOymyO-g_06CaZ5bRYdjpk2v64MXC_P821LiVvKCS1F0vb02h-qY101Tb37Y_kALjQ46g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Method for treating cardiovascular disease through adjunctive photodynamic therapy</title><source>esp@cenet</source><creator>HUGH L. NARCISO JR</creator><creatorcontrib>HUGH L. NARCISO JR</creatorcontrib><description>Photodynamic Therapy (PDT) is used as an adjunctive or stand alone procedure for the treatment of cardiovascular disease. When used as an adjunctive therapy to Percutaneous Transluminal Coronary Angioplasty, laser angioplasty, atherectomy, stenting, or any other interventional or surgical procedure, it has been found that the treatment timing is critical to the success of the combined therapies. A photosensitizer is administered prior to the surgical or interventional procedure and then readministered after the procedure to maintain the photosensitizer concentration level in the atheromatous plaque and smooth muscle cells in the vicinity of the lesion for a period of about 5-18 days, the period in which cell proliferation can occur. The photosensitizer inhibits smooth muscle cell proliferation and, thus, minimizes or eliminates the possibility of re-stenosis. The photosensitizer is then illuminated at the end of this period, thereby lysing the atheromatous plaque and smooth muscles. The photosensitizer inhibits atheromatic smooth muscle cell proliferation.</description><edition>6</edition><language>eng</language><subject>ELECTROTHERAPY ; HUMAN NECESSITIES ; HYGIENE ; MAGNETOTHERAPY ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; RADIATION THERAPY ; ULTRASOUND THERAPY</subject><creationdate>1996</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=19960801&amp;DB=EPODOC&amp;CC=AU&amp;NR=670820B2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25562,76317</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=19960801&amp;DB=EPODOC&amp;CC=AU&amp;NR=670820B2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>HUGH L. NARCISO JR</creatorcontrib><title>Method for treating cardiovascular disease through adjunctive photodynamic therapy</title><description>Photodynamic Therapy (PDT) is used as an adjunctive or stand alone procedure for the treatment of cardiovascular disease. When used as an adjunctive therapy to Percutaneous Transluminal Coronary Angioplasty, laser angioplasty, atherectomy, stenting, or any other interventional or surgical procedure, it has been found that the treatment timing is critical to the success of the combined therapies. A photosensitizer is administered prior to the surgical or interventional procedure and then readministered after the procedure to maintain the photosensitizer concentration level in the atheromatous plaque and smooth muscle cells in the vicinity of the lesion for a period of about 5-18 days, the period in which cell proliferation can occur. The photosensitizer inhibits smooth muscle cell proliferation and, thus, minimizes or eliminates the possibility of re-stenosis. The photosensitizer is then illuminated at the end of this period, thereby lysing the atheromatous plaque and smooth muscles. The photosensitizer inhibits atheromatic smooth muscle cell proliferation.</description><subject>ELECTROTHERAPY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MAGNETOTHERAPY</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>RADIATION THERAPY</subject><subject>ULTRASOUND THERAPY</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>1996</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNyrEKwjAQgOEsDqK-w72AUCqoqxXFxUV0LkdybVJqLlwuhb69Dj6A0z98_9I87qSeHXQsoEKoIfZgUVzgCbMtIwq4kAkzgXrh0ntAN5RoNUwEybOymyO-g_06CaZ5bRYdjpk2v64MXC_P821LiVvKCS1F0vb02h-qY101Tb37Y_kALjQ46g</recordid><startdate>19960801</startdate><enddate>19960801</enddate><creator>HUGH L. NARCISO JR</creator><scope>EVB</scope></search><sort><creationdate>19960801</creationdate><title>Method for treating cardiovascular disease through adjunctive photodynamic therapy</title><author>HUGH L. NARCISO JR</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_AU670820BB23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>1996</creationdate><topic>ELECTROTHERAPY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MAGNETOTHERAPY</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>RADIATION THERAPY</topic><topic>ULTRASOUND THERAPY</topic><toplevel>online_resources</toplevel><creatorcontrib>HUGH L. NARCISO JR</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>HUGH L. NARCISO JR</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Method for treating cardiovascular disease through adjunctive photodynamic therapy</title><date>1996-08-01</date><risdate>1996</risdate><abstract>Photodynamic Therapy (PDT) is used as an adjunctive or stand alone procedure for the treatment of cardiovascular disease. When used as an adjunctive therapy to Percutaneous Transluminal Coronary Angioplasty, laser angioplasty, atherectomy, stenting, or any other interventional or surgical procedure, it has been found that the treatment timing is critical to the success of the combined therapies. A photosensitizer is administered prior to the surgical or interventional procedure and then readministered after the procedure to maintain the photosensitizer concentration level in the atheromatous plaque and smooth muscle cells in the vicinity of the lesion for a period of about 5-18 days, the period in which cell proliferation can occur. The photosensitizer inhibits smooth muscle cell proliferation and, thus, minimizes or eliminates the possibility of re-stenosis. The photosensitizer is then illuminated at the end of this period, thereby lysing the atheromatous plaque and smooth muscles. The photosensitizer inhibits atheromatic smooth muscle cell proliferation.</abstract><edition>6</edition><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_AU670820BB2
source esp@cenet
subjects ELECTROTHERAPY
HUMAN NECESSITIES
HYGIENE
MAGNETOTHERAPY
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
RADIATION THERAPY
ULTRASOUND THERAPY
title Method for treating cardiovascular disease through adjunctive photodynamic therapy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T03%3A09%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=HUGH%20L.%20NARCISO%20JR&rft.date=1996-08-01&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EAU670820BB2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true